What did William Blair change in its March 10, 2026 note on TENX?

William Blair maintained an **Outperform** on Tenax Therapeutics on March 10, 2026. The note emphasized potential upside from the LEVEL trial and did not include a price target. This TENX analyst rating was a hold of prior conviction rather than an upgrade or downgrade.

Does the William Blair note include a TENX price target?

No, the William Blair publication on March 10, 2026 did not list a price target. The firm reiterated Outperform but left valuation guidance blank, so the TENX analyst rating gives directional view without a numeric target.

How should investors interpret a maintained Outperform TENX analyst rating?

A maintained **Outperform** means the analyst still expects above-average returns relative to peers. For TENX this reflects confidence in clinical catalysts. Investors should balance that view with Tenax’s small **$66,703,750** market cap and binary clinical risk.

Where can I follow updates on the TENX analyst rating and news?

Monitor the StreetInsider report for William Blair commentary and Meyka AI for real-time tracking. We publish updates to our TENX page and include analyst notes like this TENX analyst rating when they appear.

Analyst Ratings

William Blair Maintains Outperform on Tenax Therapeutics (TENX) March 2026

ByDanny Kontos March 12, 2026March 12, 2026

On March 10, 2026 William Blair maintained an Outperform on Tenax Therapeutics, Inc. (TENX), marking the newest TENX analyst rating for the micro-cap biotech. William Blair cited potential for “multifold upside” if positive top-line data arrive from the LEVEL trial. The broker left no price target in the bulletin and the stock showed a 0.76% ($0.11) move after the note. We track this as part of our real-time coverage at Meyka AI, where we note market cap at $66,703,750 and a current Meyka stock grade of B+